RT Journal Article
SR Electronic
A1 Mosley, Mary
T1 Harnessing Genomics and Molecular Profiling in ER-Positive BC for New Therapies
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 56
SP 4
OP 5
DO 10.1177/1559897715571081
UL http://mdc.sagepub.com/content/14/56/4.abstract
AB Genomic analysis and molecular profiling identified mutations and translocations in ER+ breast cancer that are targets for genome-directed therapeutics. ESR1 mutations and translocations contribute to endocrine therapy resistance. Novel pharmacologic approaches have successfully treated ESR1 Y537 mutation-driven resistance, mutant HER2 tumors, and wild-type RB and TP53 tumor suppressor function in preclinical and clinical work.